Annual report pursuant to Section 13 and 15(d)

Summary of significant accounting policies (Tables)

v2.4.0.8
Summary of significant accounting policies (Tables)
12 Months Ended
Jul. 31, 2013
Accounting Policies [Abstract]  
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category:

    Years ended July 31,  
    2013     2012     2011  
Revenue category         (in %)           (in %)           (in %)  
Medicare   $ 12,497       22     $ 12,658       21     $ 11,856       22  
Third-party payers     26,014       47       29,616       50       24,335       46  
Patient self-pay     12,172       22       11,895       20       11,554       22  
HMO’s     5,206       9       5,234       9       5,017       10  
Total   $ 55,889       100 %   $ 59,403       100 %   $ 52,762       100 %
Schedule Of Accounts Receivable By Segment [Table Text Block] The following is a table of the Company’s net accounts receivable by segment.

    July 31, 2013     July 31, 2012  
Net accounts receivable by segment         (in %)           (in %)  
Clinical Labs (by billing category)                                
Medicare   $ 930       13     $ 1,270       16  
Third party payers     3,395       46       3,478       45  
Patient self-pay     2,696       37       2,655       35  
HMO’s     300       4       330       4  
Total Clinical Labs     7,321       100 %     7,733       100 %
                                 
Total Life Sciences     4,967               6,402          
Total accounts receivable – net   $ 12,288             $ 14,135          
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] Changes in the Company’s allowance for doubtful accounts are as follows:

    July 31, 2013     July 31, 2012  
Beginning balance   $ 3,273     $ 3,488  
Provision for doubtful accounts     4,496       5,104  
Write-offs     (5,062 )     (5,319 )
Ending balance   $ 2,707     $ 3,273  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31:

    2013     2012     2011  
Numerator:                        
Net loss   $ (18,237 )   $ (39,269 )   $ (12,960 )
                         
Denominator:                        
Weighted-average common shares outstanding - Basic     39,607       38,798       38,357  
Add: effect of dilutive stock options and restricted stock                  
Weighted-average common shares outstanding - Diluted     39,607       38,798       38,357  
                         
Net loss per share                        
Basic and diluted   $ (0.46 )   $ (1.01 )   $ (0.34 )
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:

    2013     2012     2011  
Cost of clinical laboratory services   $ 10     $ 10     $ 10  
Research and development     2       4       14  
Selling, general and administrative     533       705       1,025  
    $ 545     $ 719     $ 1,049